1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

  • May 2016
  • 424 pages
  • ID: 3664418
In this report:
DESPITE THE TOTAL GROWTH OF THE ##EU MENINGOCOCCAL VACCINE MARKET AT A CAGR OF ##.##%, PFIZER'S SALES DURING THE FORECAST PERIOD WILL ONLY GROW FROM $##M IN 2015 TO $##M IN 2025, DRIVEN SOLELY BY THE LAUNCH OF TRUMENBA, AS PFIZER'S MENB VACCINE WILL CONTRIBUTE ABOUT ##% OF PFIZER'S TOTAL SALES IN THE ##EU.

Summary

Table of Contents

Search Inside

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

Brief

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses quickly. Even with appropriate treatment, up to 10.0 percent of all cases still result in death within 24 to 48 hours of symptom onset. This quick onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs established on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories contain monovalent vaccines targeting serogroup C, vaccines protecting against most serogroup B strains, and tetravalent vaccines protecting against serogroups A, C, W, and Y. While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the different serogroups.

Key Findings

Key questions & answers

- Established on interviews with leading opinion leaders, GlobalData has identified main unmet needs in the meningococcal vaccine marketplace.

- What will be the effect of new and imminent changes in national immunization schedules?

- How will the additional first-in-class vaccine covering all principal serogroups be received in the various markets?

- What research and development strategies will companies leverage to compete in the future meningococcal vaccine marketplace?

- Which patient population are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?

Main highlights

- GlobalData projects the meningococcal vaccine market in the U.S., 5EU, Japan (JP), and Brazil (BR) to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a CAGR of 5.40 percent. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Farther growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil (BR) and Japan (JP) will experience a decline at a negative Compound annual growth rate of 1.80 percent and 0.90 percent respectively.

- With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the main unmet need to be addressed in the oncoming years.

- GlobalData anticipates that alternatives will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by several governmental institutions.

Overview

- Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.

- Topline meningococcal vaccine market revenue from 2015-2025. New acquisitions, approvals and governmental recommendations are included in the forecast model.

- Key topics covered include tactical competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.

- Pipeline analysis: exhaustive data split across distinct phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

- Analysis of the current and future market competition in the overall meningococcal vaccine marketplace. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

The market research will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline.

- Develop strategic management by understanding the trends shaping and driving the overall meningococcal vaccine market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the meningococcal vaccine market in the outlook.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analyzing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cholera Vaccines Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2018 - 2025

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2018 - 2025

  • $ 5950
  • Industry report
  • August 2018
  • by Grand View Research

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025The ...

Global Veterinary Vaccines Industry

Global Veterinary Vaccines Industry

  • $ 5600
  • Industry report
  • September 2018
  • by Global Industry Analysts

This report analyzes the worldwide markets for Veterinary Vaccines in US$ by the following Product Segments: Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine ...

Vaccines Market by Technology, Disease, Route, Patient, Type - Global Forecast to 2023

Vaccines Market: Global Forecast until 2023

  • $ 5649
  • Industry report
  • August 2018
  • by MarketsandMarkets

Global vaccines market projected to grow at a CAGR of 6.7%The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, ...

Cancer Vaccines: Analytical Tool $ 3950 September 2018


Download Unlimited Documents from Trusted Public Sources

Vaccine Market and Influenza Statistics in India and the US

  • October 2018
    6 pages
  • Vaccine  

    Influenza  

    Hospital  

  • United States  

    India  

View report >

Hospital Industry in Canada - Forecast

  • October 2018
    9 pages
  • Hospital  

    Health Care Pro...  

    Influenza  

  • Canada  

    North America  

View report >

Vaccine Market in the UK

  • October 2018
    33 pages
  • Vaccine  

    Influenza  

    Healthcare  

  • United Kingdom  

View report >

Vaccine Market 9 days ago


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on